What Aidy users actually want
Mimir analyzed 14 public sources — app reviews, Reddit threads, forum posts — and surfaced 15 patterns with 8 actionable recommendations.
Top recommendation
AI-generated, ranked by impact and evidence strength
Build a clinically validated symptom tracker that captures the 8 data points required for ACG treatment guidelines and Partial Mayo scoring
Rationale
23 sources confirm patients are told to keep symptom diaries but receive no guidance on what to track or why. The 2025 ACG guidelines recommend treat-to-target strategy using patient-reported outcomes, and the Partial Mayo score relies on 3 specific variables: stool frequency, rectal bleeding, and urgency. Current tracking lacks structure, leaving patients guessing and doctors unable to use the data clinically.
Tracking reduces hospital admissions by 14 percent and improves quality-of-care scores from 50 to 84 percent when done correctly. The evidence shows 100 percent of tracked patients initiated treatment at flare onset versus 10 percent of controls, and 40.6 percent of tracked patients received intervention calls due to concerning scores. This is not incremental improvement, this is the difference between catching flares early and waiting until they require hospitalization.
Without structured tracking aligned to clinical assessment tools, the app generates data doctors cannot use and patients abandon because they don't see value. Implement a daily tracker that prompts for stool frequency, blood presence and amount, urgency episodes, pain location and intensity, nocturnal diarrhea, fatigue rating, and weight, with visual aids like Bristol Stool Scale and plain language explanations of why each metric matters for disease monitoring.
More recommendations
7 additional recommendations generated from the same analysis
13 sources show 83 to 100 percent of UC patients experience fatigue and abdominal pain during active disease, yet fatigue is the most underaddressed symptom in UC care. Patients do not report systemic symptoms like fatigue, fever, and weight loss to their GI team because these seem unrelated to bowel disease. This causes diagnostic delays and missed early warning signals.
16 sources document a critical gap: patient-reported symptoms correlate poorly with actual disease activity. Only 50 percent of Crohn's patients in clinical remission had endoscopic remission in the SONIC trial. Up to 54 percent of IBD patients have histologic inflammation despite no symptoms. Asymptomatic patients with elevated fecal calprotectin had 53 to 83 percent probability of relapsing within 2 to 3 months.
18 sources show diet tracking is burdensome without automation, and IBD patients need to identify food triggers but current tools require too much effort. Individual responses vary dramatically, making general dietary guidance insufficient. Patients reduce food intake driven by pain, nausea, and fear of triggering symptoms, a behavioral response that worsens malnutrition. This fear-driven avoidance is harmful but understandable without data showing which foods actually cause problems.
11 sources confirm patients cannot articulate symptom patterns from memory during appointments, and care teams lack visibility into what happens between clinic visits. Most IBD patients only see their GI a few times annually, and symptoms fluctuate significantly between appointments. The evidence shows tracked patients had 1.55 versus 2.34 annual outpatient visits, indicating better timed intervention.
15 sources show users want personalized, bite-sized educational content grounded in scientific credibility. Educational pathway starts with foundational content then progresses to specialized topics, targeting both newly diagnosed and experienced patients. The evidence shows content must address IBS subtypes, age-specific considerations like IBD after 50, and distinguish between Crohn's and UC. Standard content does not address diverse patient needs across different disease presentations.
18 sources show alcohol and UC relationship is the most common question patients ask, demonstrating high user interest in lifestyle-disease correlations. Individual substance responses vary dramatically: some patients tolerate alcohol, others flare from a single drink. General advice is insufficient. Alcohol increases UC flare risk with relative risk of 2.62, and interacts with common UC medications causing liver damage risk with methotrexate and disrupting thiopurine metabolism.
10 sources show users can only export or delete data via email request to info@aidyhq.com, not self-service in-app deletion. This adds friction to user control despite privacy positioning emphasizing GDPR, CCPA compliance, no advertising, no data selling, and encryption. The app collects sensitive health data including digestive disorder diagnosis, symptom ratings, stool characteristics, diet entries, and personal notes.
The full product behind this analysis
Mimir doesn't just analyze — it's a complete product management workflow from feedback to shipped feature.
Themes emerge from the noise.
Ranked by severity and frequency, with the original quotes inline so you can judge for yourself.
Talk to your research.
Ask questions, get answers grounded in what your users actually said.
What's the top churn signal?
Onboarding confusion appears in 12 of 16 sources. Users describe “not knowing where to start” [Interview #3, NPS]
A prioritized backlog, not a wall of sticky notes.
Ranked by impact and effort, with the reasoning you can actually defend in a roadmap review.
PRDs, briefs, emails — on demand.
Generate documents that reference your actual research, not generic templates.
Paste, upload, or connect.
Transcripts, CSVs, PDFs, screenshots, Slack, URLs.
This analysis used public data only. Imagine what Mimir finds with your customer interviews and product analytics.
Try with your data